Supraja Yeturi, MD
Rheumatology · Opelousas, LANPI 1528346251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 420 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by Amgen at 26.9% of the total. Reporting peaked in 2019 at $1,995 and has fallen 77.3% since, to $453 in 2025. That places this record below the midpoint for rheumatology clinicians in LA, where the typical reported total is $8,351.
Across 420 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$932
- UCB, Inc.$515
- Johnson & Johnson$442
- Lilly USA, LLC$425
- Radius Health, Inc.$390
- plus $3K from 18 others
What the payments were for
- Food & beverage$7,19198%
- Education$1842%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 112 | $1,985 |
| AbbVie | 56 | $932 |
| UCB, Inc. | 36 | $515 |
| Johnson & Johnson | 14 | $442 |
| Lilly USA, LLC | 29 | $425 |
| Radius Health, Inc. | 21 | $390 |
| Pfizer | 22 | $385 |
| GSK | 19 | $295 |
| Mallinckrodt Hospital Products Inc. | 12 | $280 |
| Genentech USA, Inc. | 14 | $260 |
| Novartis | 13 | $252 |
| E.r. Squibb & Sons, L.L.C. | 18 | $195 |
| AstraZeneca(2 entities) | 11 | $190 |
| Bristol Myers Squibb | 11 | $181 |
| Aurinia Pharma U.S., Inc. | 10 | $171 |
| Mallinckrodt Enterprises LLC | 11 | $161 |
| Boehringer Ingelheim | 1 | $85 |
| Regeneron Healthcare Solutions, Inc. | 3 | $70 |
| Sanofi | 2 | $44 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Sobi, Inc | 1 | $28 |
| Ardelyx, Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Zyla Life Sciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,375 in reported general payments places this provider in the 45th percentile of 88 rheumatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 37 | $517,750 |
| Humira(Cf) PenAdalimumab | 45 | $325,672 |
| Orencia ClickjectAbatacept | 54 | $302,775 |
| RinvoqUpadacitinib | 48 | $300,096 |
| Xeljanz XrTofacitinib Citrate | 45 | $270,163 |
| Enbrel SureclickEtanercept | 29 | $240,325 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $173,402 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 21 | $158,748 |
| BenlystaBelimumab | 28 | $131,799 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 16 | $127,766 |
| BivigamImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $117,355 |
| Cosentyx (2 Syringes)Secukinumab | 14 | $103,310 |
| Actemra ActpenTocilizumab | 20 | $89,440 |
| OtezlaApremilast | 12 | $60,629 |
| Mycophenolate Mofetil | 166 | $40,908 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $85 | $517,75037 claims |
| AbbVieRinvoq | $932 | $300,09648 claims |
| GSKBenlysta | $295 | $131,79928 claims |
| NovartisCosentyx (2 Syringes) | $252 | $103,31014 claims |
| AmgenOtezla | $1,985 | $60,62912 claims |
| PfizerEliquis | $385 | $6,23111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 88 rheumatology providers in Louisiana.
Other rheumatology in Opelousas
- Aaron BroadwellShreveport$1.6M
- Ladislas LazaroLafayette$265K
- Jerry PoundsMetairie$252K
- Carl GauthierHammond$219K
- Malik SpadyCovington$160K
- Sean ShannonBaton Rouge$157K
- Stephen LindseyBaton Rouge$130K
- Agnes SolonAlexandria$123K
- Randall BeylBaton Rouge$112K
- Frankie PedigoShreveport$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.